Alert on Giant African Snail infestation in Alappuzha district
The Kerala Centre for Pest Management (KCPM) under the Agriculture department has issued an alert over Giant African Snail infestation in Alappuzha.
Officials said here on Wednesday that with the onset of the monsoon, the widespread presence of African Snail has been observed in various parts of the district. The KCPM has urged both farmers and the public to remain vigilant against the pest, which damages crops. Since the secretions of African snails might contain parasites capable of causing diseases in humans, it is essential to handle and control them with extreme caution. 'Effective eradication is possible only through coordinated, community-based control measures,' the KCPM said in a statement.
Given that the nematodes found in the secretions of African snails have the potential to cause encephalitis in humans, the KCPM emphasised that large-scale awareness campaigns and control measures should be launched under local self-government institutions, the Agriculture and Health departments, and other relevant agencies.
African snails attack a variety of agricultural crops, including banana, tuber crops, ginger, turmeric, papaya, citrus fruits, and leafy vegetables, causing significant crop damage. They cause the most destruction to banana leaves. According to officials, the snails have a very high reproductive capacity.
'Both male and female reproductive organs are present in a single individual. On average, one snail can lay up to 900 eggs, of which about 90% will hatch. Under favourable conditions, they can live for seven to ten years, during which their population multiplies rapidly,' the statement added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
5 hours ago
- The Hindu
Alert on Giant African Snail infestation in Alappuzha district
The Kerala Centre for Pest Management (KCPM) under the Agriculture department has issued an alert over Giant African Snail infestation in Alappuzha. Officials said here on Wednesday that with the onset of the monsoon, the widespread presence of African Snail has been observed in various parts of the district. The KCPM has urged both farmers and the public to remain vigilant against the pest, which damages crops. Since the secretions of African snails might contain parasites capable of causing diseases in humans, it is essential to handle and control them with extreme caution. 'Effective eradication is possible only through coordinated, community-based control measures,' the KCPM said in a statement. Given that the nematodes found in the secretions of African snails have the potential to cause encephalitis in humans, the KCPM emphasised that large-scale awareness campaigns and control measures should be launched under local self-government institutions, the Agriculture and Health departments, and other relevant agencies. African snails attack a variety of agricultural crops, including banana, tuber crops, ginger, turmeric, papaya, citrus fruits, and leafy vegetables, causing significant crop damage. They cause the most destruction to banana leaves. According to officials, the snails have a very high reproductive capacity. 'Both male and female reproductive organs are present in a single individual. On average, one snail can lay up to 900 eggs, of which about 90% will hatch. Under favourable conditions, they can live for seven to ten years, during which their population multiplies rapidly,' the statement added.
India Today
8 hours ago
- India Today
Bharat Biotech and GSK cut price of world's first malaria vaccine to under $5
Hyderabad-based drugmaker Bharat Biotech and GSK have announced that the price of the world's first malaria vaccine, RTS,S, will be reduced to under $5 for children in malaria-endemic price cut is expected to improve access to the vaccine and could save thousands of young lives every announcement, made on Wednesday, is part of the companies' pledge to the Gavi Vaccine Alliance for its 2026–2030 phase. The reduced price will come into effect gradually and be fully implemented by Bharat Biotech says this price drop is possible due to improvements in manufacturing, larger production capacity, cost-effective processes, and a commitment to keeping profit margins FIRST MALARIA VACCINERTS,S is the world's first malaria vaccine recommended by the World Health Organisation (WHO). Since its recommendation in 2021, GSK has invested heavily in improving production and transferring manufacturing technology to Bharat return, Bharat Biotech has invested over $200 million in new, high-output facilities and product the end of 2025, the vaccine is expected to be part of routine immunisation programmes in 12 African countries with the support of efforts are backed by collaborations among GSK, Bharat Biotech, WHO, PATH, MedAccess, and the governments of malaria-affected countries.'This pledge is more than a price cut—it's a commitment to global equity. We are working to close the gap between vaccine supply and the urgent needs of children at risk of malaria,' said Dr. Krishna Ella, Executive Chairman of Bharat Breuer, Chief Global Health Officer at GSK, added, 'We've worked closely with Bharat Biotech and our partners to make this vaccine more affordable and accessible. Today's announcement marks a big step toward changing the future of malaria prevention.'For families and communities in regions where malaria has taken a heavy toll, the reduction in the vaccine cost could help in the global effort to control and eventually eliminate the disease.- Ends
&w=3840&q=100)
Business Standard
11 hours ago
- Business Standard
Bharat Biotech, GSK to slash malaria vaccine price to $5 per dose by 2028
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022. GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028. A phased reduction in price for the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of $5 by 2028. The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read. Malaria kills more than 500,000 people annually, mainly children aged five and under in sub-Saharan Africa, according to WHO estimates. Cases and deaths fell significantly between 2000 and 2015, but progress has since stalled and even reversed, with a particular jump in mortality during the COVID-19 pandemic. Many experts have expressed hope that vaccines can help turn the tide in the fight against the mosquito-borne disease. But price has been an issue, particularly when compared to other tools to prevent malaria like bed nets. GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, according to a spokesperson. Wednesday's announcement comes as Gavi - a global vaccine group that helps buy childhood vaccines in the world's poorest countries - holds an event in Brussels to raise funding for its work over the next five years, as governments pull back from international aid. GSK and Bharat said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine. Twelve African countries are set to introduce the vaccine in their routine immunisation programmes by the end of this year with Gavi's support. The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose.
